Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nancy Lynn Keating, M.D.

Co-Author

This page shows the publications co-authored by Nancy Keating and Matthew Smith.
Connection Strength

4.158
  1. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014 Apr; 65(4):816-24.
    View in: PubMed
    Score: 0.530
  2. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012 Oct 03; 104(19):1518-23.
    View in: PubMed
    Score: 0.516
  3. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013 Jul; 64(1):159-66.
    View in: PubMed
    Score: 0.499
  4. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 06; 102(1):39-46.
    View in: PubMed
    Score: 0.424
  5. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun; 101(11):1335-6.
    View in: PubMed
    Score: 0.382
  6. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83.
    View in: PubMed
    Score: 0.371
  7. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20; 24(27):4448-56.
    View in: PubMed
    Score: 0.339
  8. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36.
    View in: PubMed
    Score: 0.146
  9. Ultraviolet index and racial differences in prostate cancer incidence and mortality. Cancer. 2013 Sep 01; 119(17):3195-203.
    View in: PubMed
    Score: 0.135
  10. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol. 2014 Mar; 65(3):642-9.
    View in: PubMed
    Score: 0.132
  11. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013 Feb 15; 119(4):863-70.
    View in: PubMed
    Score: 0.129
  12. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28.
    View in: PubMed
    Score: 0.123
  13. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61.
    View in: PubMed
    Score: 0.115
  14. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94.
    View in: PubMed
    Score: 0.105
  15. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
    View in: PubMed
    Score: 0.043
  16. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619.
    View in: PubMed
    Score: 0.041
  17. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62.
    View in: PubMed
    Score: 0.038
  18. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30.
    View in: PubMed
    Score: 0.036
  19. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
    View in: PubMed
    Score: 0.027
  20. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.